Celcuity Inc's Comment on Sales, Marketing and Customers
The company focuses on cancer patients primarily treated by medical, surgical, or radiation oncologists, as well as the multidisciplinary teams supporting them, including nurses, advanced practitioners, and pharmacists. Its market opportunity includes approximately 37,000 patients in the U.S. with HR+/HER2- advanced breast cancer (ABC) who have progressed after treatment with a CDK4/6 inhibitor. The company competes with major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and research organizations. Notable competitors include Novartis AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd, Verastem, Inc., Gilead Sciences, Inc., BridgeBio Pharma Inc., Eli Lilly and Company, Kazia Therapeutics Limited, Relay Therapeutics, Inc., Revolution Medicines Inc., and Takeda Pharmaceutical Company Limited. Market competitiveness and pricing are influenced by reimbursement availability from government and private payors. Customers and markets identified in company filings include AstraZeneca plc, BridgeBio Pharma Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Kazia Therapeutics Limited, Novartis AG, Relay Therapeutics, Inc., Revolution Medicines Inc., Takeda Pharmaceutical Company Limited, and Verastem, Inc.
Advancements in Targeted Oncology: An Overview of Celcuity s Latest Findings and Future Directions Breast cancer remains one of the most prevalent and challenging malignancies to treat, requiring continuous efforts in research and development of new therapeutic strategies. Celcuity Inc., a clinical-stage biotechnology company, has positioned itself at the forefront of these efforts. Their pioneering work on targeted therapies offers promising avenues for managing advanced breast cancer, particularly through innovations in addressing the PIK3CA wild-type cohort and combining therapeutic agents. This article synthesizes findings from recent studies and conference presentations pivotal to the advancements in b...
Celcuity Inc., a pioneering clinical-stage biotechnology company specializing in the development of targeted therapies for oncology, has made a significant announcement that holds immense promise for patients with HR+/HER2- advanced breast cancer (ABC). The company has revealed plans to commence a Phase 3 clinical trial to investigate the efficacy of gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as the first-line treatment for patients who are resistant to endocrine therapy.Endocrine therapy resistance poses a major challenge in the management of HR+/HER2- ABC. In light of this, Celcuity s innovative approach aims to provide physicians and patients with a novel treatment option that spec...
Celcuity Inc’s Comment on Sales, Marketing and Customers
The company focuses on cancer patients primarily treated by medical, surgical, or radiation oncologists, as well as the multidisciplinary teams supporting them, including nurses, advanced practitioners, and pharmacists. Its market opportunity includes approximately 37,000 patients in the U.S. with HR+/HER2- advanced breast cancer (ABC) who have progressed after treatment with a CDK4/6 inhibitor. The company competes with major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and research organizations. Notable competitors include Novartis AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd, Verastem, Inc., Gilead Sciences, Inc., BridgeBio Pharma Inc., Eli Lilly and Company, Kazia Therapeutics Limited, Relay Therapeutics, Inc., Revolution Medicines Inc., and Takeda Pharmaceutical Company Limited. Market competitiveness and pricing are influenced by reimbursement availability from government and private payors. Customers and markets identified in company filings include AstraZeneca plc, BridgeBio Pharma Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Kazia Therapeutics Limited, Novartis AG, Relay Therapeutics, Inc., Revolution Medicines Inc., Takeda Pharmaceutical Company Limited, and Verastem, Inc.
Sources:
Celcuity Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Celcuity Inc’s corporate clients.
For your research, we’ve provided 9 tables on Celcuity Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
